Final analysis of the ZOE-LTFU trial to 11 years postvaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications

Herpes zoster (HZ) vaccines should provide durable protection against HZ and HZ-related complications. We report the final analysis of a long-term follow-up (LTFU) study (ZOE-LTFU) including 11 years of follow-up after primary vaccination with recombinant zoster vaccine (RZV).

Detalles Bibliográficos
Autores: Strezova, Ana, Díez Domingo, Javier, Cunningham, Anthony L., Eto, Takashi, Andrews, Charles, Arns, Clovis, Choo, Eun Ju, Cheong Hui, David Shu, Icardi, Giancarlo, McNeil, Shelly A., Põder, Airi, Kosina, Pavel, Rombo, Lars, Schwarz, Tino F., Tinoco, Juan Carlos, Yu, Chong-Jen, Wang, Jing, Soni, Jyoti, Tsang, Manyee, Leon, Rafael, Mwakingwe-Omari, Agnes
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/5765
Acceso en línea:http://hdl.handle.net/20.500.12466/5765
Access Level:acceso abierto
Palabra clave:Recombinant zoster vaccine
Herpes zoster
Post-herpetic neuralgia
Long-term follow-up
32 Ciencias Médicas
Descripción
Sumario:Herpes zoster (HZ) vaccines should provide durable protection against HZ and HZ-related complications. We report the final analysis of a long-term follow-up (LTFU) study (ZOE-LTFU) including 11 years of follow-up after primary vaccination with recombinant zoster vaccine (RZV).

Similares en LA Referencia